Immunotoxins Market - Databook 2025 to 2034

The global immunotoxins market size accounted for USD 152 million in 2024 and is predicted to touch around USD 337.39 million by 2034, growing at a CAGR of 8.3% from 2025 to 2034.

Highlights of the Immunotoxins Market

• North America dominated the immunotoxins market in 2024.
• APAC is expected to show the fastest growth rate in the forecasted period of 2025 to 2034.
• By product, the diphtheria Toxin (DT) segment held the biggest market share in 2024.
• By product, the pseudomonas Exotoxin segment is expected to show the fastest growth rate in the forecasted period of 2025 to 2034.
• By application, the therapy development segment has contributed to the major market share in 2024.
• By application, the biomedical research segment is expected to show rapid growth in the forecasted period of 2025 to 2034.
• By End-use, the pharmaceutical & biotechnology companies segment has contributed to the maximum market share in 2024.
• By End-use, the academic and research institutes segment are expected to show the fastest growth in the forecasted period of 2025 to 2034.

Industry Valuation and Growth Rate Projection

Immunotoxins are engineered proteins that are designed specifically to target cancer-causing cells. These immunotoxins contain toxins along with an antibody that binds to the targeted cells, such as cancerous or diseased cells. Intensive market research for targeted therapy like genetic engineering, antibody technology, and toxin modification have resulted in the development of better and refined immunotoxins. The rising number of cancer cases has led to the growth of the immunotoxins market, resulting in treatments that are more precise and targeted towards curing such diseases.

Chemotherapy and Radiation therapy used in the treatment of cancer patients have adverse side effects. New technological advancements in the field of biotechnology have improved various designs and production, while decreasing the side effects such as loss of health and hair. The immunotoxins market is expected to grow faster in the forecasted period with innovations and improvements in molecular engineering to enhance specificity.

Immunotoxins Market: Stats and Figures

• In 2022, approximately 20 million new cancer cases were diagnosed worldwide, with projections estimating an increase to 35 million cases annually by 2050.
• By 2050, breast cancer diagnoses are expected to reach 3.2 million new cases annually, with associated deaths projected at 1.1 million per year, representing increases of 38% and 68%, respectively.
• The World Health Organization (WHO) forecasts a 77% rise in global cancer cases by 2050, escalating from 20 million new cases in 2022 to over 35 million.
• In 2022, nearly half of the new cancer cases occurred in Asia, which also accounted for a majority of the 9.7 million cancer deaths that year.

Industry Leader Announcements

• Kim Kelderman, Bio-Techne's President/and Chief Executive Officer”

"We are excited to partner with Thermo Fisher to expand the reach of our products and services throughout Europe, by leveraging the Fisher Scientific Channel's extensive European distribution network and industry expertise, we aim to enhance support for researchers and accelerate scientific discoveries that address some of the most pressing challenges in healthcare today."

• Dr. Roland Green, CEO of Invenra

“We are honored to partner with the Astellas team, one of the world’s foremost developers of therapeutics. We are excited by the potential of this partnership to yield profound benefits to patients in need.”

How AI Has Benefitted the Market

The immunotoxins market has seen immense growth with the introduction of AI. Such AI-powered tools help in the early diagnosis and prediction of cancer by analyzing genetically and clinical data and accelerate research by analyzing different data and predicting drug efficacy, thus aiding drug discovery and development.

• AI can help provide personalized treatment plans with sheer precision based on genetic and clinical data, ensuring effectiveness.
• AI helps develop the most complex gene therapy, like CRISPR to treat immunodeficiencies, enhancing the accuracy and success rates with it.
• AI and Machine learning have become an integral part of understanding previous operations and predicting immunodeficiencies through data-driven insights and suggest the most effective cure.

Geographical Insights

The immunotoxins market has experienced significant growth, where North America contributes to the major market share with the Asia Pacific region showing the fastest growth and Europe following along.

North America

In 2024, North America has contributed the biggest share in the immunotoxins market holding the major share of 41.45% of the market. The region's dominance in this market is due to the advancements in the healthcare sector and the rising number of cancer patients. Several factors play a key role in such a big market share:

• Presence of leading biotechnology firms that help in the research & development and spread awareness about gene and cell therapy.
• Government initiatives and investments have also played a key role in increasing the research & development of such advanced therapies, replacing radiation and chemotherapy, which have major side effects with immunotherapies.

China and APAC

China and the Asia-Pacific region are expected to show the fastest grow in the immunotoxins market. The adoption of advanced technology and increased investment in research and development for products to tackle diseases like cancer shall result in rapid growth. Several factors contribute to such rapid growth:

• The adoption of cutting-edge technology by China for innovation in biotechnology and immunotherapy with government initiatives and an increase in awareness for immunotoxins have resulted in increasing growth in the market for the region.

Europe

Europe is predicted to grow in the forecasted period with its active adoption of technology and increase in investment over the years on research and development on immunotoxins. The region experiences mergers and combinations between pharmaceutical companies in the market to grow collectively and further increase the market share by development in targeted cancer therapy.

Recent Developments:

• In April 2024, Bio-Techne entered into a strategic distribution agreement with Thermo Fisher Scientific to provide cutting-edge solutions to its customers. These two industry leaders in the fields of research, biotechnology, and diagnostics under this agreement shall distribute Bio-Techne's extensive portfolio of products to the European market through Fisher Scientific’s channel.
• In April 2024, Invenra Inc. announced a strategic research agreement with Astella Pharma for research on innovative science and use it for the value of patients. Under this agreement, Astella will have access to Invenra’s B-Body technology to advance their research further.
• In December 2024, the Researcher developed GrB-Fc-KS49, which has shown high specificity and cytotoxicity toward EMP2-positive cells, which is a biomarker overexpressed in more than 75% of breast cancer cases worldwide, also including triple-negative breast cancer (TNBC).

Competitive Landscape

The immunotoxins market is highly competitive, with leading pharmaceutical companies such as Creative Biolabs, Merck KGaA, Bio-Techne, Santa Cruz Biotechnology, Inc., List Biological Laboratories, Inc. These Companies hold a dominant position in the immunotoxins market.

The market is dominated by several pharmaceutical companies renowned for their significant contributions to cancer research and treatment. Based on recent data, the top three leading companies are:

Company Name: Creative Biolabs

Year of Incorporation: 2005

Headquarters: Ney York, United States

Creative Biolabs' immunotoxins division achieved substantial growth in the year 2024. The company has achieved a revenue of $19.6 million in the year 2024 and is rapidly growing as one of the top companies within the market.

Company Name: Merck KGaA

Year of Incorporation: 1668

Headquarters: Darmstadt, Germany

Merck's immunotoxins division achieved substantial growth, with an annual revenue of $ 64 billion in the year 2024, with a fair increase from the previous year, and is expected to grow at the same rate in the forecasted period.

Company Name: Thermo Fisher Scientific

Year of Incorporation: 2006

Headquarters: Waltham, Massachusetts

Thermo Fisher Scientific was established by a merger between Thermo Electron and Fisher Scientific. It provides many kinds of products and services throughout 600+ locations across America, APAC, and EMEA regions. It has provided a significant contribution to the immunotoxins market with a revenue of USD 42.88 Billion in the year 2024.